nach oben

Current Gastroenterology Reports

Erschienen in:

01.05.2019 | Inflammatory Bowel Disease (S Hananauer, Section Editor)

Novel Non-biologic Targets for Inflammatory Bowel Disease

verfasst von: Tushar Shukla, Bruce E. Sands

Erschienen in: Current Gastroenterology Reports | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The biologic era revolutionized the medical management of inflammatory bowel disease (IBD) and allowed for a paradigm shift away from a therapeutic strategy that traditionally relied on corticosteroids and immunomodulators. IBD treatment has now further evolved to encompass novel non-biologic agents.

Recent Findings

An electronic database search, spanning up to September 2018, was conducted using PubMed, Web of Science, Google Scholar, and Scopus. Abstracts were also reviewed from Digestive Diseases Week, European Crohn’s and Colitis Organization congress, Canadian Digestive Diseases Week, and United European Gastroenterology Week.

Summary

The JAK1/3 inhibitor, tofacitinib, was shown to both induce and maintain clinical remission and mucosal healing in ulcerative colitis (UC). Also, the sphingosine-1-phosphate (SIP) S1P1/S1P5 receptor agonist ozanimod showed benefit with clinical remission and mucosal healing in UC. Anti-trafficking non-biologic therapies such as AJM300 and a phosphodiesterase (PDE) PDE4 inhibitor, apremilast, have shown benefit in terms of clinical response, clinical remission, and mucosal healing in UC. Upadacitinib and filgotinib have shown initial favorable outcomes in CD patients, with further ongoing trials. Non-biologic agents comprise a growing number of mechanisms of action with the promise of safe and effective oral therapy for patients with IBD.

Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol. 2018;11:1558–70. https://doi.org/10.1038/s41385-018-0050-3.CrossRefPubMedPubMedCentral

Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol. 2018;24:3567–82.CrossRef

Targan SR, Hanauer SB, van Deventer SJH, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn’s disease. N Engl J Med. 1997;337:1029–36.CrossRef

Eustace GJ, Melmed GY. Therapy for Crohn’s disease: a review of recent developments. Curr Gastroenterol Rep. 2018;20:2066.CrossRef

Click B, Regueiro M. A practical guide to the safety and monitoring of new IBD therapies. Inflamm Bowel Dis. 2018;107:1409.

Amiot A, Peyrin-Biroulet L. Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Ther Adv Gastroenterol. 2015;8:66–82.CrossRef

Hanauer SB. New targets for small molecules in inflammatory bowel disease. Gastroenterol Hepatol. 2015;11:338–40.

Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199–209.CrossRef

Vermeire S, Gils A, Accossato P, Lula S, Marren A. Immunogenicity of biologics in inflammatory bowel disease. Ther Adv Gastroenterol. 2018;11:1756283X1775035. https://doi.org/10.1177/1756283X17750355.CrossRef

10.

Bots S, Gecse K, Barclay M, D’Haens G. Combination immunosuppression in IBD. Inflamma Bowel Dis. 2018;24:539–45.CrossRef

11.

White JR, Phillips F, Monaghan T, Fateen W, Samuel S, Ghosh S, et al. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment Pharmacol Ther. 2018;47:1610–22.CrossRef

12.

Fiorino G, D’Amico F, Italia A, Gilardi D, Furfaro F, Danese S. JAK inhibitors: novel developments in management of ulcerative colitis. Best Pract Res Clin Gastroenterol. 2018;32–33:89–93.CrossRef

13.

Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38:127–42.CrossRef

14.

Fernández-Clotet A, Castro-Poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Rev Clin Immunol. 2018;14:881–92.CrossRef

15.

Flamant M, Rigaill J, Paul S, Roblin X. Advances in the development of Janus kinase inhibitors in inflammatory bowel disease: future prospects. Drugs. 2017;77:1057–68.CrossRef

16.

Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16:495–503.CrossRef

17.

Marsolais D, Rosen H. Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov. 2009;8:297–307.CrossRef

18.

Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest. 2015;125:1379–87.CrossRef

19.

Saruta M, Papadakis KA. Lymphocyte homing antagonists in the treatment of inflammatory bowel diseases. Gastroenterol Clin N Am. 2014;43:581–601.CrossRef

20.

Greuter T, Vavricka SR, Biedermann L, Pilz J, Borovicka J, Seibold F, et al. Alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment for left-sided ulcerative colitis and ulcerative Proctitis. Dig Dis. 2018;36:123–9.CrossRef

21.

Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583–90.CrossRef

22.

Sandborn WJ, Ghosh S, Panés J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. Mass Med Soc. 2012;367:616–24.CrossRef

23.

• Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36 Pivotal trial demonstrating the efficacy and safety of tofacitinib as an induction and maintenance agent in ulcerative colitis. CrossRef

24.

Sands BE, Moss AC, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, et al. Sa1761—efficacy and safety of dose escalation to tofacitinib 10 mg bid for patients with ulcerative colitis following loss of response on tofacitinib 5 mg bid maintenance therapy: results from OCTAVE Open. Gastroenterology. 2018;154:S–385.CrossRef

25.

Colombel JF. Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention. Inflamm Bowel Dis. 2018;24:2173–82.CrossRef

26.

Winthrop KL, Melmed GY, Vermeire S, Long MD, Chan G, Pedersen RD, et al. Herpes zoster infection in patients with ulcerative colitis receiving Tofacitinib. Inflamm Bowel Dis. 2018;24:2258–65.CrossRef

27.

• Sandborn WJ, Ghosh S, Panés J, Vranic I, Wang W, Niezychowski W, et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:1485–1493.e2 This trial showed that tofacitinib is not effective in Crohn’s disease patients. CrossRef

28.

Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D’Haens G, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049–59.CrossRef

29.

D’Amico F, Fiorino G, Furfaro F, Allocca M, Danese S. Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials. Expert Opin Investig Drugs. 2018;27:595–9.CrossRef

30.

• Sandborn WJ, Feagan BG, Panés J, D’Haens GR, Colombel JF, Zhou Q, et al. Safety and efficacy of ABT-494 (Upadacitinib), an oral Jak1 inhibitor, as induction therapy in patients with Crohn’s disease: results from Celest. Gastroenterology. 2017;152:S1308–9 This trial demonstrated that updacitinib may be an efficacious induction agent in the treatment of Crohn’s disease patients who have failed anti-TNF therapy. CrossRef

31.

Schreiber S, Peyrin-Biroulet L, Boland BS, Higgins PD, Armuzzi A, Terdiman JP, et al. Sa1755—rapidity of clinical and laboratory improvements following upadacitinib induction treatment: data from the Celest study. Gastroenterology. 2018;154:S382–3.CrossRef

32.

ClinicalTrialsGov. A study to evaluate the safety and efficacy of upadacitinib (ABT-494) for induction and maintenance therapy in subjects with moderately to severely active ulcerative colitis (UC). NCT02819635. https://clinicaltrials.gov/ct2/show/NCT02819635?term=NCT02819635&rank=1, Accessed November 27, 2018.

33.

• Vermeire S, Schreiber S, Petryka R, Kuehbacher T, Hebuterne X, Roblin X, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–75 This trial showed that filgotinib is a potentially efficacious agent in the induction of clinical remission in CD. CrossRef

34.

ClinicalTrialsGov. Filgotinib in long-term extension study of adults with Crohn’s disease. NCT02914600. https://clinicaltrials.gov/ct2/show/NCT02914600?term=inflammatory+bowel+disease&cond=filgotinib&rank=2, Accessed November 27, 2018.

35.

ClinicalTrialsGov. Efficacy and safety of filgotinib in the treatment of small bowel Crohn’s disease (SBCD). NCT03046056. https://clinicaltrials.gov/ct2/show/NCT03046056?term=inflammatory+bowel+disease&cond=Filgotinib&rank=3, Accessed November 27, 2018.

36.

ClinicalTrialsGov. Filgotinib in the induction and maintenance of remission in adults with moderately to severely active Crohn’s disease. NCT02914561. https://clinicaltrials.gov/ct2/show/NCT02914561?term=inflammatory+bowel+disease&cond=Filgotinib&rank=4, Accessed November 27, 2018.

37.

ClinicalTrialsGov. Efficacy and safety of filgotinib in the treatment of perianal fistulizing Crohn’s disease. NCT03077412. https://clinicaltrials.gov/ct2/show/NCT03077412?term=inflammatory+bowel+disease&cond=Filgotinib&rank=5, Accessed November 27, 2018.

38.

ClinicalTrialsGov. Filgotinib in long-term extension study of adults with ulcerative colitis. NCT02914535. https://clinicaltrials.gov/ct2/show/NCT02914535?term=inflammatory+bowel+disease&cond=Filgotinib&rank=6, Accessed November 27, 2018.

39.

ClinicalTrialsGov. Filgotinib in the induction and maintenance of remission in adults with moderately to severely active ulcerative colitis (SELECTION1). https://clinicaltrials.gov/ct2/show/NCT02914522?term=inflammatory+bowel+disease&cond=Filgotinib&rank=8, Accessed November 27, 2018.

40.

Sands BE, Sandborn WJ, Feagan BG, Lichtenstein GR, Zhang H, Strauss R, et al. Peficitinib, an Oral Janus kinase inhibitor, in moderate-to-severe ulcerative colitis: results from a randomized, phase 2 study. J Crohns Colitis. 2018;126:1158–69.CrossRef

41.

Beattie D, Tsuruda P, Shen F, Brassil P, Langrish C, Janc J, et al. TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor. 11^th Congress of ECCO. 2016;S123.

42.

Sandborn WJ, Bhandari R, Leighton J, Ganeshappa R, Nguyen D, Ferslew B, et al. The intestinally restricted, orally administered, pan-JAK inhibitor TD-1473 demonstrates favorable safety, tolerability, pharmacokinetics, and signal for clinical activity in subjects with moderately-to-severely active ulcerative colitis. United European Gastroenterology J 2018; 6 (Supplement 1).

43.

ClinicalTrialsGov. Efficacy and safety of TD-1473 in Crohn’s disease (DIONE). NCT03635112. https://clinicaltrials.gov/ct2/show/NCT03635112?term=TD-1473&cond=inflammatory+bowel+disease&rank=3, Accessed November 27, 2018.

44.

Kappos L, Radue E-W, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.CrossRef

45.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:1–12.CrossRef

46.

Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.CrossRef

47.

Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.CrossRef

48.

US Food and Drug Administration. Gilenya (fingolimod) prescribing information. http://www.pharma. us.novartis.com/product/pi/pdf/gilenya.pdf, Accessed November 27, 2018

49.

Nielsen OH, Li Y, Johansson-Lindbom B, Coskun M. Sphingosine-1-phosphate signaling in inflammatory bowel disease. Trends Mol Med. 2017;23:362–74.CrossRef

50.

• Sandborn WJ, Feagan BG, Wolf DC, D’Haens G, Vermeire S, Hanauer SB, et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016;374:1754–62 This trial demonstrated that ozanimod may be a viable and safe induction and maintenance agent in ulcerative colitis. CrossRef

51.

Sandborn W, Feagan B, D’Haens G, Hanauer S, Wolf D, Vermeire S, et al. Safety and efficacy of long-term treatment with ozanimod: an oral S1P receptor modulator, in moderate to severe ulcerative colitis—TOUCHSTONE extension 2-year follow-up. AJG. 2017;112:S319–429.CrossRef

52.

ClinicalTrialsGov. Open-label extension of RPC1063 as therapy for moderate to severe ulcerative colitis. NCT02531126. https://clinicaltrials.gov/ct2/show/NCT02531126?term=Ulcerative+colitis&cond=Ozanimod&rank=1, Accessed November 27, 2018.

53.

ClinicalTrialsGov. Safety and efficacy trial of RPC1063 for moderate to severe ulcerative colitis. NCT02435992. https://clinicaltrials.gov/ct2/show/NCT02435992?term=Ulcerative+colitis&cond=Ozanimod&rank=2, Accessed November 27, 2018.

54.

Feagan B, Sandborn W, Danese S, D’Haens G, Levesque B, Wolf D, et al. Endoscopic and clinical efficacy demonstrated with oral ozanimod in moderately to severely active Crohn’s disease. AJG. 2017;112:S319–429.CrossRef

55.

ClinicalTrialsGov. Induction study #1 of oral ozanimod as induction therapy for moderately to severely active Crohn’s disease. NCT03440372. https://clinicaltrials.gov/ct2/show/NCT03440372?term=NCT03440372&rank=1, Accessed November 27, 2018.

56.

ClinicalTrialsGov. Induction study #2 of oral ozanimod as induction therapy for moderately to severely active Crohn’s disease. NCT03440385. https://clinicaltrials.gov/ct2/show/NCT03440385?term=NCT03440385&rank=1, Accessed November 27, 2018.

57.

ClinicalTrialsGov. An extension study of oral ozanimod for moderately to severely active Crohn’s disease. NCT03467958. https://clinicaltrials.gov/ct2/show/NCT03467958?term=NCT03467958&rank=1, Accessed November 27, 2018.

58.

ClinicalTrialsGov. A placebo-controlled study of oral ozanimod as maintenance therapy for moderately to severely active Crohn’s. NCT03464097. https://clinicaltrials.gov/ct2/show/NCT03464097?term=NCT03464097&rank=1, Accessed November 27, 2018.

59.

Peyrin-Biroulet L, Gatlin J, Soloman M, Unett D, Al-Shamma H, Behan D. Receptor profile and efficacy of Etrasimod (APD334), an oral, next-generation sphingosine-1-phosphate receptor modulator in development for ulcerative colitis. United European Gastroenterology J; 2016; 2 (Supplement 1).

60.

Sandborn W, Peyrin-Biroulet L, Trokan L, Zhang J, Kuhbacher T, Chiorean M, et al. A randomized, double-blind, placebo-controlled trial of selective, oral sphingosine 1-phosphate receptor modulator, Etrasimod (APD334), in moderate to severe ulcerative colitis: results from the oasis study. United European Gastroenterology J 2018; 6 (Supplement 1).

61.

Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:579–94.CrossRef

62.

• Yoshimura N, Watanabe M, Motoya S, Tominaga K, Matsuoka K, Iwakiri R, et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology. 2015;149:1775–1783.e2 This trial demonstrated that AJM300 may be an efficacious and safe agent in the treatment of ulcerative colitis. Clinical response, remission, and mucosal healing endpoints were all achieved. CrossRef

63.

Takazoe M, Watanabe M, Kawaguchi T, Matsumoto T, Oshitani N, Hiwatashi N, et al. S1066-oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease—a randomized, double-blind. Placebo-Controlled Trial Gastroenterol. 2009;136:A181.

64.

ClinicalTrialsGov. A study to evaluate the safety and efficacy of AJM300 in participants with active ulcerative colitis. NCT03531892. https://clinicaltrials.gov/ct2/show/NCT03531892?term=ajm300&rank=1, Accessed November 27, 2018.

65.

Sandborn WJ, Bressler B, Lee S, Bhandari R, Kanwar B, Tozzi L, et al. PTG-100, an oral gut-restricted peptide a4B7 antagonist, induces clinical and histologic remisison in patients with moderate to severely active ulcerative colitis. United European Gastroenterology J 2018. 6 (Supplement 1).

66.

Yacyshyn BR, Chey WY, Goff J, Salzberg B, Baerg R, Buchman AL, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn’s disease. Gut. 2002;51:30–6.CrossRef

67.

Yacyshyn B, Chey WY, Wedel MK, Yu RZ, Paul D, Chuang E. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn’s disease. Clin Gastroenterol Hepatol. 2007;5:215–20.CrossRef

68.

Miner PB, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23:1403–13.CrossRef

69.

van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB. A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther. 2006;23:1415–25.CrossRef

70.

Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: a case series. United European Gastroenterol J. 2016;4:97–104.CrossRef

71.

ClinicalTrialsGov. Efficacy of alicaforsen in pouchitis patients who have failed to respond to at least one course of antibiotics. NCT02525523. https://clinicaltrials.gov/ct2/show/NCT02525523?term=NCT02525523&rank=1, Accessed November 27, 2018.

72.

• Danese S, Neurath M, Kopon A, Zakko S, Simmons T, Fogel R, et al. Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. 13^th Congress of ECCO. 2018;S004. This trial showed that a greater proportion of apremilast treated UC patients may achieve clinical remission, endoscopic score improvement, and mucosal healing compared to placebo.

73.

ClinicalTrialsGov. Efficacy and safety study of apremilast to treat active ulcerative colitis. NCT02289417. https://clinicaltrials.gov/ct2/show/NCT02289417?term=apremilast&cond=inflammatory+bowel+disease&rank=1, Accessed November 27, 2018.

74.

Keating GM. Apremilast: a review in psoriasis and psoriatic arthritis. Drugs. 2017;77:459–72.CrossRef

75.

Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, Bernardini S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn’s disease. Mol Ther. 2012;20:870–6.CrossRef

76.

Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, Castiglione F, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015;372:1104–13.CrossRef

77.

Keshav S, Vaňásek T, Niv Y, Petryka R, Howaldt S, Bafutto M, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn’s disease. PLoS One. 2013;8:e60094.CrossRef

78.

Feagan BG, Sandborn WJ, D’Haens G, Lee SD, Allez M, Fedorak RN, et al. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn’s disease. Aliment Pharmacol Ther. 2015;42:1170–81.CrossRef

79.

D’Haens G, Sandborn WJ, Colombel JF, Rutgeerts P, Brown K, Barkay H, et al. A phase II study of laquinimod in Crohn’s disease. Gut. 2015;64:1227–35.CrossRef

80.

Karner M, Kocjan A, Stein J, Schreiber S, Boyen von G, Uebel P, et al. First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in Mesalazine-refractory courses. Am J Gastroenterol. 2014;109:1041–51.CrossRef

Titel: Novel Non-biologic Targets for Inflammatory Bowel Disease
verfasst von: Tushar Shukla
Bruce E. Sands
Publikationsdatum: 01.05.2019
Verlag: Springer US
Erschienen in: Current Gastroenterology Reports / Ausgabe 5/2019
Print ISSN: 1522-8037
Elektronische ISSN: 1534-312X
DOI: https://doi.org/10.1007/s11894-019-0689-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen